NASDAQ:CELU Celularity Q4 2024 Earnings Report $0.76 +0.01 (+0.76%) Closing price 04:00 PM EasternExtended Trading$0.76 +0.00 (+0.13%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Celularity EPS ResultsActual EPS-$0.59Consensus EPS -$1.50Beat/MissBeat by +$0.91One Year Ago EPSN/ACelularity Revenue ResultsActual Revenue$18.13 millionExpected Revenue$5.20 millionBeat/MissBeat by +$12.93 millionYoY Revenue GrowthN/ACelularity Announcement DetailsQuarterQ4 2024Date5/8/2025TimeBefore Market OpensConference Call DateFriday, May 9, 2025Conference Call Time4:00PM ETUpcoming EarningsCelularity's Q1 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Celularity Earnings HeadlinesCelularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental ...June 5, 2026 | markets.businessinsider.comCelularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell TherapiesJune 4, 2026 | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.June 22 at 1:00 AM | Porter & Company (Ad)Celularity Releases CEO Letter to ShareholdersJune 3, 2026 | globenewswire.comCelularity Appoints Rick Gonzalez as Chief Commercial OfficerJune 3, 2026 | globenewswire.comCelularity Receives Nasdaq Notice Regarding Form 10-QMay 29, 2026 | globenewswire.comSee More Celularity Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email. Email Address About CelularityCelularity (NASDAQ:CELU) is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens. The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells. Among its lead investigational candidates is a placental-derived NK cell therapy being evaluated in both oncology and immuno-infectious disease settings. Celularity also explores exosome-based approaches to deliver therapeutic proteins and RNA payloads to specific tissues. Founded by Dr. Robert L. Hariri—who previously established and led Celgene’s cellular therapeutic research efforts—Celularity went public in April 2021 via a special purpose acquisition company (SPAC) transaction and now trades on the Nasdaq under the symbol CELU. The company is headquartered in Florham Park, New Jersey, with research and manufacturing operations designed to support scalable production of its cell therapy candidates. Under the leadership of President and Chief Executive Officer Robert L. Hariri, M.D., Ph.D., Celularity brings together a team of experts in cell biology, process development and clinical research. The company maintains collaborations with academic centers and industry partners to advance its portfolio through clinical trials, with the goal of delivering novel, off-the-shelf therapies to patients worldwide.View Celularity ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Buy CrowdStrike Before the Stock Split? Here's the CaseUSA Today's Digital Revival Is Gaining Steam, But With Plenty of RiskBurlington Is Winning Over Shoppers But Investors Need PatienceInvestors Are Buying Into Sweetgreen Again—Should They?Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE?3 Oil Refiners Built to Cash In on Higher Crack SpreadsSatellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Upcoming Earnings FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
